| CUSTOMERS |
CUSTOMERS |
85%
|
In conducting our business, we process, transmit and store sensitive personal and medical data about our customers |
| ACET |
Adicet Bio, Inc. |
72%
|
l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any new intellectual property generated by ATP… |
| ACET |
Adicet Bio, Inc. |
72%
|
Reciprocal relationship from ACET graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from ACET graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from ACET g… |
| ALLO |
Allogene Therapeutics, Inc. |
72%
|
Reciprocal relationship from ALLO graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from ALLO g… |
| ALLO |
Allogene Therapeutics, Inc. |
72%
|
l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any new intellectual property generated by ATP… |
| FATE |
Fate Therapeutics, Inc. |
72%
|
l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any new intellectual property generated by ATP… |
| FATE |
Fate Therapeutics, Inc. |
72%
|
Reciprocal relationship from FATE graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from FATE g… |
| GILD |
Gilead Sciences, Inc. |
72%
|
l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any new intellectual property generated by ATP… |
| GILD |
Gilead Sciences, Inc. |
72%
|
Reciprocal relationship from GILD graph: Reciprocal relationship from GDTC graph: l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorpo… |
| IMTX |
Immatics N.V. |
72%
|
l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any new intellectual property generated by ATP… |
| IMTX |
Immatics N.V. |
72%
|
Reciprocal relationship from IMTX graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from IMTX graph: Reciprocal relationship from GDTC graph: l expansion. ATPL retained the righ… |
| IPSC |
Century Therapeutics, Inc. |
72%
|
Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from GDTC graph: l expansion. ATPL retained the righ… |
| IPSC |
Century Therapeutics, Inc. |
72%
|
l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any new intellectual property generated by ATP… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any new intellectual property generated by ATP… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from GDTC graph: l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorp… |
| ACCELERATE-TECHNOLOGIES-PTE-LTD |
ACCELERATE-TECHNOLOGIES-PTE-LTD |
62%
|
ty, and availability of data, in compliance with the necessary legislation and regulations in the jurisdictions in which we operate. In order to ensure our adherence to the necessary legislation and … |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
ct in currencies other than our respective functional currencies (“foreign currencies”). Currency risk arises when transactions are denominated in foreign currencies other than functional currency. I… |
| COMPANY-THE-GROUP |
COMPANY-THE-GROUP |
62%
|
expense and as a corresponding adjustment to equity over the remaining vesting period, unless the revision to original estimates is due to market conditions. No adjustment is made if the revision or … |
| CORDLIFE-GROUP-LIMITED |
CORDLIFE-GROUP-LIMITED |
62%
|
ure and, therefore, our future success depends on the successful and continued market acceptance of this service. Broad use and acceptance of our service requires marketing expenditures and education… |
| CYTOMED-THERAPEUTICS-PTD-LTD |
CYTOMED-THERAPEUTICS-PTD-LTD |
62%
|
ty, and availability of data, in compliance with the necessary legislation and regulations in the jurisdictions in which we operate. In order to ensure our adherence to the necessary legislation and … |
| CYTOMED-THERAPEUTICS-PTE-LTD |
CYTOMED-THERAPEUTICS-PTE-LTD |
62%
|
ty, and availability of data, in compliance with the necessary legislation and regulations in the jurisdictions in which we operate. In order to ensure our adherence to the necessary legislation and … |
| EMERGING-GROWTH-COMPANY |
EMERGING-GROWTH-COMPANY |
62%
|
lish research or reports about our business or if they publish negative reports or downgrade our shares, the price of our Ordinary Shares could decline. The trading market for our Ordinary Shares rel… |
| EXPLOIT-TECHNOLOGIES-PTE-LTD |
EXPLOIT-TECHNOLOGIES-PTE-LTD |
62%
|
ty, and availability of data, in compliance with the necessary legislation and regulations in the jurisdictions in which we operate. In order to ensure our adherence to the necessary legislation and … |
| IMPAIRMENT-THE-GROUP |
IMPAIRMENT-THE-GROUP |
62%
|
e disclosed in Note 6 to the consolidated financial statements. On August 22, 2025, the Company transferred its entire equity interest in Puricell Lab Pte Ltd (“Puricell Lab”) to its subsidiary, Long… |
| INVESTMENT-IN-AN-ASSOCIATE-THE-GROUP |
INVESTMENT-IN-AN-ASSOCIATE-THE-GROUP |
62%
|
gages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity); ● whose operating … |
| LANDMARK-MEDICAL-CENTRE-SDN-BHD-THE-GROUP |
LANDMARK-MEDICAL-CENTRE-SDN-BHD-THE-GROUP |
62%
|
gages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity); ● whose operating … |
| LONGEVITYBANK-PTE-LTD |
LONGEVITYBANK-PTE-LTD |
62%
|
on of CellSafe International Sdn. Bhd. (In-Liquidation) through our subsidiary LongevityBank Pte. Ltd. (previously known as iPSCBank Pte Ltd) may lead to unforeseen financial and operational difficul… |
| PURICELL-LAB-PTE-LTD |
PURICELL-LAB-PTE-LTD |
62%
|
e disclosed in Note 6 to the consolidated financial statements. On August 22, 2025, the Company transferred its entire equity interest in Puricell Lab Pte Ltd (“Puricell Lab”) to its subsidiary, Long… |
| SZE-LINCOLN-LUK-TIEN-WEN-CYTOMED-THERAPEUTICS-PT |
SZE-LINCOLN-LUK-TIEN-WEN-CYTOMED-THERAPEUTICS-PT |
62%
|
ty, and availability of data, in compliance with the necessary legislation and regulations in the jurisdictions in which we operate. In order to ensure our adherence to the necessary legislation and … |
